ongitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients - Longitudinal analysis of non-small cell lung cancer-specific immunity

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•Histologically or cytologically proven irresectable stage III or IV non-small cell lung cancer
•Age above 18 years
•Performance score: WHO 0, 1 or 2 at the time of study entry
•Written informed consent
•Specific inclusion criteria for tissue biopsies:
•- Only target lesion with limited biopsy-procedure related complication risk will be sampled; For instance easily accessible peripheral lymph nodes, subcutaneous, pleural, liver metastastasis.
•- Other lesions will only be included if there is a clinical necessity for tissue analysis (e.g. molecular profiling, resection metastasis in case of oligometastastic disease).
•- Only non-irradiated lesions will be sampled

•Severe anemia (Hb < 6.0 mmol/L)
•Any bleeding disorder or anti-coagulation therapy, that cannot be discontinued or corrected, that significantly increases the risk of a bleeding due to the biopsy.

发起方

Antoni van Leeuwenhoek Ziekenhuis